KUALA LUMPUR: Pharmaniaga Bhd
saw its profit after tax surge more than threefold to RM8.7mil in the fourth quarter ended Dec 31, 2025 (4Q25) from RM2.4mil a year earlier, marking its eighth consecutive profitable quarter and reinforcing its financial recovery as it moves towards exiting PN17.
The pharmaceutical said the encouraging 4Q25 performance was supported by sustained demand in the concession segment, steady manufacturing performance, and continued cost optimisation across the group’s operations.
Quarterly revenue rose 1.3% to RM938.3mil from RM926.4mil a year earlier, while earnings per share increased to 0.21 sen from 0.16 sen previously.
For the full financial year ended Dec 31, 2025, Pharmaniaga posted a net profit of RM48.5mil on a 4.5% rise in revenue to RM3.93bil.
“FY25 marked a key milestone for Pharmaniaga, with the completion of our Regularisation Plan (RP) and the achievement of the eighth consecutive profitable quarter, bolstering our progress towards exiting PN17,” managing director Datuk Zulkifli Jafar said.
“These position the group to strengthen its core businesses and pursue sustainable growth moving forward, underpinned by the resilience and discipline across our operations,” he added.
Zulkifli said the manufacturing division continued to be a key contributor to the group’s operating performance, with a positive long-term outlook supported by the ongoing expansion of the group’s vaccine manufacturing business and sustained demand for generic medicines.
“Our biopharmaceutical segment recorded full-year sales of RM13mil in 2025, supported by strong demand for Hepatitis B and Influenza vaccines. We expect this positive momentum to continue in 2026, driven by a growing number of corporate vaccination programmes,” he said.
He added that the development of its PCV13 and Hexavalent vaccines is progressing well with government grant support, further strengthening Pharmaniaga’s biopharmaceutical capabilities and long-term growth pipeline.
“The launch of five new pharmaceutical products has contributed positively to sales in 2025. This year, we will roll out six more major products to strengthen our portfolio and capture growing demand, particularly within the private healthcare market,” Zulkifli said.
Meanwhile, he noted that order volumes from government hospitals increased by 9% in 2025 compared with the previous financial year, driven by the expansion of the Approved Product Purchase List (APPL), which is expected to grow from nearly 850 to over 1,200 products, supporting higher volumes and improved profitability.
Looking ahead, Zulkifli said the group remains focused on advancing its biopharmaceutical and pharmaceutical pipelines, supported by rising vaccine demand, new product launches and continued expansion of the APPL.
“In parallel, we are strengthening operational efficiency through digitalisation and supply chain optimisation, while progressing our regional growth strategy in Indonesia.”
